1 Cash-Heavy Stock to Target This Week and 2 We Ignore [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability. Not all businesses with cash are winners, and that's why we built StockStory - to help you separate the good from the bad. That said, here is one company with a net cash position that can leverage its balance sheet to grow and two best left off your watchlist. Two Stocks to Sell: 10x Genomics (TXG) Net Cash Position: $439 million (16% of Market Cap) Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ:TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context. Why Do We Think TXG Will Underperform? Sales trends were unexciting over the last two years as its 1.9% annual growth was below the typical healthcare company Smaller revenue base of $642.8 million means it hasn't achieved the econo
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- 10x Genomics to Participate in the BofA Securities 2026 Healthcare ConferencePR Newswire
- 10x Genomics (TXG) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- 10x Genomics (TXG) had its price target raised by Canaccord Genuity Group Inc. from $22.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- 10x Genomics (TXG) had its price target raised by Bank of America Corporation from $21.00 to $30.00. They now have a "neutral" rating on the stock.MarketBeat
- 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood [Yahoo! Finance]Yahoo! Finance
TXG
Earnings
- 2/12/26 - Beat
TXG
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/28/26 - Form SCHEDULE
- 4/24/26 - Form DEFA14A
- TXG's page on the SEC website